on Theranexus (EPA:ALTHX)
Theranexus Reveals its Cash Position as of June 30, 2025
Theranexus, a biopharmaceutical company specializing in rare neurological diseases, announced its cash position at €2.1 million as of June 30, 2025, compared to €2.9 million as of March 31, 2025. A reimbursement of the 2024 Research Tax Credit of €754,000 is expected in the third quarter of 2025, thus providing financial visibility until the second quarter of 2026.
Mathieu Charvériat, CEO of Theranexus, highlights the importance of the strategic collaboration with Exeltis and the progress made on the Batten-1 project. Theranexus continues to innovate by launching a new antisense oligonucleotide, while maintaining its goal of creating sustainable value for its shareholders through innovative solutions for rare neurological diseases.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news